Grazoprevir/elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV/HIV co-infection: a non-randomized, open-label clinical trial

Background and aims: We aimed to evaluate the efficacy and tolerability of grazoprevir/elbasvir in patients with chronic genotype 1 hepatitis C virus (HCV) and HIV co-infection who experienced peginterferon alfa plus ribavirin (PegIFN/RBV) (clinicaltrials.gov NCT03098121). Methods: This non-randomiz...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Yi-Chun, Li, Shih-Wei, Ku, Shin-Yen, Hsieh, Hui-Ting, Lin, Mei-Hui, Chang, Shu-Yin, Wu, Wei-Wei, Sun, Na-Lee, Cheng, Shu-Hsing, Cheng, Chien-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489556/
https://www.ncbi.nlm.nih.gov/pubmed/31114268
http://dx.doi.org/10.2147/IDR.S206938

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489556/
https://www.ncbi.nlm.nih.gov/pubmed/31114268
http://dx.doi.org/10.2147/IDR.S206938

Ejemplares similares